Veracyte Stock Fundamentals
| VCYT Stock | USD 31.51 1.08 3.55% |
Veracyte fundamentals help investors to digest information that contributes to Veracyte's financial success or failures. It also enables traders to predict the movement of Veracyte Stock. The fundamental analysis module provides a way to measure Veracyte's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Veracyte stock.
Veracyte |
Veracyte Company Return On Equity Analysis
Veracyte's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Veracyte Return On Equity | 0.0218 |
Most of Veracyte's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Veracyte is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, Veracyte has a Return On Equity of 0.0218. This is 100.09% lower than that of the Biotechnology sector and 100.06% lower than that of the Health Care industry. The return on equity for all United States stocks is 107.03% lower than that of the firm.
Veracyte Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Veracyte's current stock value. Our valuation model uses many indicators to compare Veracyte value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Veracyte competition to find correlations between indicators driving Veracyte's intrinsic value. More Info.Veracyte is rated second in return on equity category among its peers. It is rated second in return on asset category among its peers reporting about 0.64 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Veracyte is roughly 1.57 . Comparative valuation analysis is a catch-all technique that is used if you cannot value Veracyte by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Veracyte Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Veracyte's direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Veracyte could also be used in its relative valuation, which is a method of valuing Veracyte by comparing valuation metrics of similar companies.Veracyte is currently under evaluation in return on equity category among its peers.
Veracyte Fundamentals
| Return On Equity | 0.0218 | ||||
| Return On Asset | 0.0139 | ||||
| Profit Margin | 0.05 % | ||||
| Operating Margin | 0.07 % | ||||
| Current Valuation | 2.17 B | ||||
| Shares Outstanding | 77.94 M | ||||
| Shares Owned By Insiders | 0.84 % | ||||
| Shares Owned By Institutions | 99.22 % | ||||
| Number Of Shares Shorted | 3.13 M | ||||
| Price To Earning | (10.61) X | ||||
| Price To Book | 2.05 X | ||||
| Price To Sales | 5.32 X | ||||
| Revenue | 445.76 M | ||||
| Gross Profit | 309.7 M | ||||
| EBITDA | 49.2 M | ||||
| Net Income | 24.14 M | ||||
| Cash And Equivalents | 170.11 M | ||||
| Cash Per Share | 2.37 X | ||||
| Total Debt | 50.74 M | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 4.09 X | ||||
| Book Value Per Share | 15.12 X | ||||
| Cash Flow From Operations | 75.1 M | ||||
| Short Ratio | 3.63 X | ||||
| Earnings Per Share | 0.31 X | ||||
| Target Price | 44.44 | ||||
| Number Of Employees | 824 | ||||
| Beta | 1.8 | ||||
| Market Capitalization | 2.37 B | ||||
| Total Asset | 1.3 B | ||||
| Retained Earnings | (443.98 M) | ||||
| Working Capital | 293.63 M | ||||
| Current Asset | 47.91 M | ||||
| Current Liabilities | 14.72 M | ||||
| Net Asset | 1.3 B |
About Veracyte Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Veracyte's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Veracyte using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Veracyte based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis Prosigna Breast Cancer Assay for breast cancer diagnosis Percepta Genomic Sequencing Classifier and Percepta Nasal Swab Test for lung cancer diagnosis Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis and Immunoscore Colon Cancer test for colon cancer diagnosis. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California. Veracyte operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 761 people.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Veracyte Stock Analysis
When running Veracyte's price analysis, check to measure Veracyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Veracyte is operating at the current time. Most of Veracyte's value examination focuses on studying past and present price action to predict the probability of Veracyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Veracyte's price. Additionally, you may evaluate how the addition of Veracyte to your portfolios can decrease your overall portfolio volatility.